EP Patent

EP2550964A1 — Temsirolimus for use in the prevention and/or treatment of a delta 9-tetrahydrocannabinol-induced anxiety disorder

Assigned to Universitat Pompeu Fabra UPF · Expires 2013-01-30 · 13y expired

What this patent protects

The invention relates to temsirolimus for use as a medicament to prevent and/or treat a Δ9-tetrahydrocannabinol-induced anxiety disorder and to compositions comprising both agents.

USPTO Abstract

The invention relates to temsirolimus for use as a medicament to prevent and/or treat a Δ9-tetrahydrocannabinol-induced anxiety disorder and to compositions comprising both agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP2550964A1
Jurisdiction
EP
Classification
—
Expires
2013-01-30
Drug substance claim
No
Drug product claim
No
Assignee
Universitat Pompeu Fabra UPF
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.